Darwinweg 24
Leiden 2333 CR
Netherlands
31 71 524 7400
https://www.pharming.com
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 382
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Dr. Sijmen de Vries M.B.A., M.D. | President, CEO & Executive Director | 1.44M | N/A | 1959 |
Mr. Jeroen Wakkerman | Chief Financial Officer | N/A | N/A | 1969 |
Ms. Mireille Sanders M.Sc. | Chief Operations Officer | N/A | N/A | 1968 |
Susanne Embleton | Investor Relations Manager | N/A | N/A | N/A |
Mr. Ruud Van Outersterp | Chief Ethics & Compliance Officer | N/A | N/A | 1964 |
Dr. Anurag Relan M.D., MPH | Chief Medical Officer | N/A | N/A | 1972 |
Mr. Stephen Toor | Chief Commercial Officer & GM Americas | N/A | N/A | 1971 |
Dr. Alexander Breidenbach M.B.A. | Chief Business Officer | N/A | N/A | 1964 |
Dr. Bruno M. L. Giannetti | Consultant | N/A | N/A | 1952 |
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.
Pharming Group N.V.’s ISS governance QualityScore as of 1 May 2024 is 1. The pillar scores are Audit: 7; Board: 1; Shareholder rights: 3; Compensation: 1.